{
    "clinical_study": {
        "@rank": "46925", 
        "arm_group": {
            "arm_group_label": "Enzalutamide", 
            "arm_group_type": "Experimental", 
            "description": "Oral therapy with enzalutamide at 160mg (4 capsules) orally once daily (QD)."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to see how long it takes for prostate cancer to come back in\n      patients who have had surgery to remove their prostate gland (radical prostatectomy), while\n      being treated with enzalutamide (formerly known as MDV3100).\n\n      Enzalutamide is known as an androgen-receptor signaling inhibitor, which means that it\n      blocks activity of the male hormone, testosterone. Most prostate cancers are dependent on\n      testosterone for growth. In this study, patients will take enzalutamide after surgery to see\n      if it keeps their cancer from coming back."
        }, 
        "brief_title": "Enzalutamide in Patients With High-risk Prostate Cancer", 
        "condition": "Adenocarcinoma of the Prostate", 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Prostatic Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a pilot phase II study evaluating the clinical activity and safety of Enzalutamide\n      (formerly known as MDV3100) a novel androgen receptor (AR) inhibitor in men with high-risk\n      prostate cancer who have undergone local definitive therapy with radical prostatectomy.\n\n      Primary Objectives:\n\n      -To evaluate the clinical efficacy of enzalutamide in patients with high-risk prostate\n      cancer with regards to: Time to disease progression defined by biochemical recurrence (BCR)\n\n      Secondary Objectives:\n\n      -To further evaluate the safety of enzalutamide in patients with high-risk prostate cancer\n\n      Exploratory Objectives:\n\n        -  To determine the presence of circulating tumor cells in patients with high-risk\n           prostate cancer.\n\n        -  To describe the effects of enzalutamide on the number of circulating tumor (CTCs) in\n           patients who have detectable CTCs prior to study entry.\n\n      Patients will receive daily oral therapy with enzalutamide at 160mg (4 capsules) orally once\n      daily (QD). Patients will continue on study until progressive disease, drug intolerability,\n      consent withdrawal or completion of study at 24 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Understand and voluntarily sign an informed consent form.\n\n          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n\n          -  Histologically confirmed adenocarcinoma of the prostate.\n\n          -  Patients must have undergone a Radical Prostatectomy (any surgical technique is\n             permitted) within 3 months from study entry and have high-risk disease define by any\n             of the following:\n\n               -  Pathological stage T3a, T3b, T4 (any grade or iPSA)\n\n               -  Gleason' sum > 8 (any stage or iPSA)\n\n               -  Initial Pre-operative PSA > 20ng/mL (any GS or pT stage)\n\n               -  Any stage/PSA/Gleason patients with a 35% or greater chance of biochemical\n                  failure at 5 years based on Kattan's nomogram\n                  http://nomograms.mskcc.org/Prostate/PostRadicalProstatectomy.\n\n               -  Patients with Lymph node (LN) positive disease, regardless of iPSA, pT stage or\n                  GS provided their post-operative PSA 6-8 weeks after surgery is < 0.4ng/mL.\n                  (Lymph node dissection is desired but not mandated)\n\n          -  Able to swallow the study drug and comply with study requirements.\n\n          -  Patients must have normal organ and marrow function as defined below:\n\n               -  Testosterone > 50 ng/dL per laboratory reference range\n\n               -  Baseline Post-RP PSA < 0.4\n\n               -  Hemoglobin \u2265 10.0 g/dL independent of transfusion\n\n               -  Absolute neutrophil count >1,500/mcL\n\n               -  Platelet count \u2265100,000/\u00ecL\n\n               -  Serum albumin \u2265 3.5 g/dL\n\n               -  Serum potassium \u2265 3.5 mmol/L\n\n               -  Liver function: serum bilirubin < 1.5 x ULN (except for patients with documented\n                  Gilbert's disease) and AST or ALT < 2.5 x ULN\n\n        Exclusion Criteria:\n\n          -  Testosterone > 50 ng/dL per laboratory reference range\n\n          -  Baseline Post-RP PSA < 0.4\n\n          -  Hemoglobin \u2265 10.0 g/dL independent of transfusion\n\n          -  Absolute neutrophil count >1,500/mcL\n\n          -  Platelet count \u2265100,000/\u00ecL\n\n          -  Serum albumin \u2265 3.5 g/dL\n\n          -  Serum potassium \u2265 3.5 mmol/L\n\n          -  Liver function: serum bilirubin < 1.5 x ULN (except for patients with documented\n             Gilbert's disease) and AST or ALT < 2.5 x ULN pelvis and/or whole body bone scan\n             (WBS) within 4 weeks from study entry.\n\n          -  History of seizure or any condition that may predispose to seizure (e.g., prior\n             cortical stroke, significant brain trauma). Also, history of loss of consciousness or\n             transient ischemic attack within 12 months of enrollment.\n\n          -  Clinically significant cardiovascular disease including:\n\n               -  Myocardial infarction within 6 months prior to Screening;\n\n               -  Uncontrolled angina within 3 months prior to Screening;\n\n               -  Congestive heart failure New York Heart Association (NYHA) class 3 or 4, or\n                  patients with history of congestive heart failure NYHA class 3 or 4 in the past,\n                  unless a screening echocardiogram (ECHO) or multi-gated acquisition scan (MUGA)\n                  performed within 3 months results in a left ventricular ejection fraction that\n                  is \u2265 45%\n\n               -  History of clinically significant ventricular arrhythmias (e.g., ventricular\n                  tachycardia, ventricular fibrillation, torsades de pointes)\n\n               -  History of Mobitz II second degree or third degree heart block without a\n                  permanent pacemaker in place\n\n               -  Hypotension as indicated by systolic blood pressure < 86 mmHg at the Screening\n                  visit\n\n               -  Bradycardia as indicated by a heart rate of < 50 beats per minute on the\n                  Screening ECG\n\n               -  Uncontrolled hypertension as indicated by systolic blood pressure > 170 mmHg or\n                  diastolic blood pressure > 105 mmHg at the Screening visit\n\n          -  Gastrointestinal disorder affecting absorption (e.g., Gastrectomy, active peptic\n             ulcer disease within last 3 months)\n\n          -  Any condition or reason that, in the opinion of the Investigator, interferes with the\n             ability of the patient to participate in the trial, which places the patient at undue\n             risk, or complicates the interpretation of safety data.\n\n          -  The effects of enzalutamide on the developing human fetus at the recommended\n             therapeutic doses are unknown. Thus, men must agree to use adequate contraception\n             (barrier method of birth control or abstinence) prior to study entry, for the\n             duration of study participation, and for 6 months after the usage of enzalutamide.\n             Should the patient's partner become pregnant or suspect she is pregnant while the\n             patient is participating in this study, the patient should inform his treating\n             physician immediately."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "42", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01927627", 
            "org_study_id": "CASE12812", 
            "secondary_id": "NCI-2013-01661"
        }, 
        "intervention": {
            "arm_group_label": "Enzalutamide", 
            "description": "oral therapy with enzalutamide at 160mg (4 capsules) orally once daily (QD).", 
            "intervention_name": "enzalutamide", 
            "intervention_type": "Drug", 
            "other_name": [
                "XTANDI", 
                "MDV3100"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Prostate cancer", 
            "adenocarcinoma of the prostate", 
            "Enzalutamide"
        ], 
        "lastchanged_date": "May 22, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Cleveland", 
                    "country": "United States", 
                    "state": "Ohio", 
                    "zip": "44195"
                }, 
                "name": "Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center"
            }, 
            "investigator": {
                "last_name": "Jorge Garcia, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 2 Study of Enzalutamide in Patients With High-risk Prostate Cancer Who Have Undergone Local Definitive Therapy With Radical Prostatectomy", 
        "other_outcome": {
            "description": "Quantify mRNA levels of Survivin in CTCs obtained from patients pre- and post-treatment with enzalutamide using the Veridex Cell Search Profile kit.", 
            "measure": "Impact of enzalutamide on circulating tumor cells (CTCs)", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "overall_contact": {
            "email": "garciaj4@ccf.org", 
            "last_name": "Jorge Garcia, MD", 
            "phone": "216-444-7774"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Serologic criteria is a PSA value > 0.4 in two separate occasions at least two weeks apart.", 
            "measure": "Time to progression, defined by serologic criteria.", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01927627"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To further evaluate the number of patients that experience adverse events related to the study drug. NCI Cancer Clinical Trials Common Toxicity Criteria (version 4.0)will be utilized.", 
            "measure": "Safety of enzalutamide", 
            "safety_issue": "Yes", 
            "time_frame": "2 years"
        }, 
        "source": "Case Comprehensive Cancer Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Case Comprehensive Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}